Timothy Eugene Sullivan - 28 Jan 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: Chief Financial Officer
Issuer ticker: APLS
Reported as of: 28 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jan 2026, 16:07:47 UTC
Prior SEC filing: 23 Jan 2026
Next SEC filing: 20 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ David Watson, attorney-in-fact for Timothy Sullivan

Key filing fact

Timothy Eugene Sullivan filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 30 Jan 2026.

Key facts

This page summarizes Timothy Eugene Sullivan's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Jan 2026, 16:07.

Change

Previous filing in this sequence was filed on 23 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001707000 Primary reporting owner

Sullivan Timothy Eugene

Relationship: Chief Financial Officer
Address: C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM
Signature: /s/ David Watson, attorney-in-fact for Timothy Sullivan
Signature date: 30 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Common Stock

Award

Transaction value: $0
Shares: +58,140
Change %: +62%
Price: $0.000000
Shares after: 152,041
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

APLS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 60,396
Date: 28 Jan 2026
Ownership: The Timothy E Sullivan Irrevocable Trust of 2023
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

Footnote F2

The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.